Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according to Goldman Sachs.
Get this delivered to your inbox, and more info about our products and services.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
BioAge Labs' novel obesity treatment could boost the biotechnology company's stock, the Wall Street bank says.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, according…
The investment bank upgraded the pharma stock to overweight from equal weight.
Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support…
